Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 156 participants.
Also called NCT03408639
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 156 participants
- Sponsor
- Cinnagen
- Registry
-
NCT03408639
-
- Other papers using this trial's data
- Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Iran
- Registry status
- Completed
Technical summary
Registry record NCT03408639. Randomized; quadruple masking; primary purpose treatment. Start 2016-06-22 (actual); primary completion 2017-07-19 (actual). Results posted on 2019-11-06.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients
- Condition
- Anemia in End-Stage Renal Disease
- Intervention (Drug)
- CinnaPoietin®
- Intervention (Drug)
- Eprex®
- Intervention (Drug)
- Nephrovit
- Intervention (Drug)
- Vitamin B12 Injection
- Lead sponsor
- Cinnagen
Record details
- Record id
cardio:ct-nct03408639- Content hash
74e0b96822d7d4c430555efe2e1d29e60124fc5d6db738c01be60a2fcc9c35ea